Equities research analysts at Robert W. Baird increased their price target on shares of Stryker (NYSE: SYK)
Several other analysts have also recently commented on the stock. Analysts at BMO Capital Markets raised their EPS on shares of Stryker in a research note to investors on Thursday. They now have a ?market perform? rating and a $65.00 price target on the stock. Separately, analysts at Mizuho raised their price target on shares of Stryker from $64.00 to $69.00 in a research note to investors on Thursday. They now have a ?buy? rating on the stock.
Seventeen investment analysts have rated the stock with a buy rating, two have assigned an overweight rating, and seventeen have issued a hold rating to the stock. The company currently has a consensus rating of ?overweight? and a consensus target price of $61.70.
Stryker traded up 2.26% on Thursday, hitting $63.27. Stryker has a 52-week low of $49.43 and a 52-week high of $61.92. The stock?s 50-day moving average is currently $57.00. The company has a market cap of $24.055 billion and a price-to-earnings ratio of 16.61.
Stryker last issued its quarterly earnings data on Wednesday, January 23rd. The company reported $1.14 earnings per share for the quarter, beating the analysts? consensus estimate of $1.13 by $0.01. The company had revenue of $2.34 billion for the quarter, compared to the consensus estimate of $2.27 billion. During the same quarter last year, the company posted $1.02 earnings per share. Stryker?s revenue was up 5.5% compared to the same quarter last year. Stryker has set its FY13 guidance at $4.25-4.40 EPS. On average, analysts predict that Stryker will post $4.30 earnings per share for the current fiscal year.
Stryker Corporation (Stryker) is a medical technology company. Stryker offers a diverse array of medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products.